Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt ...

In a report released today, Mani Foroohar from Leerink Partners maintained a Sell rating on Moderna, with a price target of $18.00. The company’s shares opened today at $28.20. Take advantage of ...

Kennedy announced in a statement Tuesday that 22 projects, totaling $500 million, to develop vaccines using mRNA technology ...

In addition to Oppenheimer, Moderna also received a Hold from Citi’s Geoff Meacham in a report issued today. However, on the same day, Bank of America Securities reiterated a Sell rating on Moderna ...

US Health and Human Services is “winding down” its mRNA vaccine development and will instead fund other vaccine platforms ...

The company posted strong second-quarter results and reaffirmed its guidance for 2025. Enbridge posted EBITDA of C$4.6 ...

US Health Secretary Robert F. Kennedy Jr says the administration is focusing on coming up with a universal vaccine, replacing ...

The U.S. Department of Health and Human Services said on Tuesday it would wind down mRNA vaccine development activities under ...

Farmacia Moderna wins the 14th edition of the five-a-side football tournament "United against ALS", but what counts most are ...